Artelo’s ART26.12 Reports Zero Adverse Events, Targets Multiple Dose Study This Year
Artelo’s Phase 1 single ascending dose study of ART26.12 showed zero adverse events and supports a potentially first-in-class FABP5 inhibitor for visceral, inflammatory, neuropathic and joint pain models. A peer-reviewed publication and planned multiple ascending dose study this year highlight ART26.12’s differentiated non-opioid profile and commercial potential.
1. Publication and Preclinical Evidence
Artelo published a peer-reviewed article demonstrating FABP5 inhibition produced analgesic effects across seven preclinical models including diabetic neuropathy, osteoarthritis, cancer bone pain and chemotherapy-induced peripheral neuropathy. The data show ART26.12 reduced pro-inflammatory mediators and modulated established pain pathways, supporting its first-in-class potential as a non-opioid treatment.
2. Phase 1 Single Ascending Dose Study
In the completed Phase 1 SAD study, ART26.12 was well tolerated with zero severe or serious drug-related adverse events across all evaluated doses. This excellent safety profile distinguishes ART26.12 from current pain therapies that face safety limitations.
3. Planned Multiple Ascending Dose Study
Artelo plans to initiate a multiple ascending dose study later this year to assess ART26.12’s safety and pharmacodynamics over repeated dosing. Positive results could position the program for Phase 2 efficacy trials and partnership interest.
4. Market Potential and Unmet Need
With 24.3% of U.S. adults experiencing chronic pain and growing concerns over opioid misuse, ART26.12’s non-opioid, non-steroidal mechanism addresses significant market demand. Success in clinical development could reshape pain management and drive commercial value for Artelo.